| T10773 |
CF53
|
1808160-52-2
|
100%
|
|
|
CF53 is a highly potent, selective and orally active inhibitor of BET protein, with a Ki of <1 nM, Kd of 2.2 nM and an IC50 of 2 nM for BRD4 BD1. CF53 binds to b...
|
| T7810 |
LY3177833
|
1627696-51-8
|
100%
|
|
|
LY3177833 is an Cdc7 kinase inhibitor (IC50 : 3.3 nM)
|
| T3352 |
XL413
|
1169558-38-6
|
100%
|
|
|
XL-413 is an orally bioavailable cell division cycle 7 homolog (CDC7) kinase inhibitor with potential antineoplastic activity. XL-413 binds to and inhibits the a...
|
| T19913 |
CKI-7
|
1177141-67-1
|
100.00%
|
|
|
CKI-7 is a potent and ATP-competitive inhibitor of casein kinase 1 (CK1; IC50: 6 μM; Ki: 8.5 μM) and a selective Cdc7 kinase inhibitor. CKI-7 also inhibits SGK, ...
|
| T3664 |
THZ1
|
1604810-83-4
|
95.09%
|
|
|
THZ1 (CDK7 inhibitor) is a novel selective and potent covalent CDK7 inhibitor.
|
| T69188 |
Aloisine B
|
496864-14-3
|
95.15%
|
|
|
Aloisine B (AloisineB) inhibited cyclin-dependent kinase and glycogen synthase kinase with IC50 values of 0.85 µM and 0.75 µM, respectively. Aloisine B has antiv...
|
| T39957 |
CDK4/6-IN-6
|
2380321-51-5
|
95.63%
|
|
|
CDK4/6-IN-6 is a potent CDK4/CDK6 inhibitor with Ki of 0.6 nM and 13.9 nM for CDK4/Cyclin D1 and CDK6/Cyclin D3, respectively.
|
| TQ0060 |
LY2857785
|
1619903-54-6
|
96.00%
|
|
|
LY2857785 is a type I competitive and reversible ATP kinase inhibitor against CDK7/CDK8/CDK9 (IC50s: 246 nM/16 nM/11 nM).
|
| T37207L |
Cdk5 Substrate acetate
|
|
96.21%
|
|
|
Cyclin-dependent kinase 5 (Cdk5) is a serine/threonine kinase that is predominantly active in neuronal tissues. With p25 or p35, Cdk5 phosphorylates a range of p...
|
| T15335 |
FN-1501
|
1429515-59-2
|
96.35%
|
|
|
FN-1501 is a potent FLT3 and CDK inhibitor (IC50s: 2.47, 0.85, 1.96, and 0.28 nM for CDK2/cyclin A, CDK4/cyclin D1, CDK6/cyclin D1 and FLT3, respectively). FN-1...
|
| T6458 |
CYC-116
|
693228-63-6
|
96.6%
|
|
|
CYC116 is a potent inhibitor of Aurora A/B with Ki of 8.0 nM/9.2 nM, is less potent to VEGFR2 (Ki of 44 nM), with 50-fold greater potency than CDKs, not active a...
|
| T5405 |
BI-1347
|
2163056-91-3
|
96.7%
|
|
|
BI-1347 is a potent, selective inhibitor of CDK8/cyclinC (IC50: 1 nM). It shows tumor growth inhibition in an in vivo xenograft model.
|
| T10740 |
CDK8-IN-1
|
1629633-48-2
|
97.09%
|
|
|
CDK8-IN-1 is a selective CDK8 inhibitor (IC50: 3 nM).
|
| T10727 |
Cdc7-IN-5
|
1402057-86-6
|
97.15%
|
|
|
Cdc7-IN-5 is a potent inhibitor of Cdc7 kinase. Cdc7, a serine-threonine protein kinase enzyme, is essential for the initiation of DNA replication in the cell cy...
|
| T60619 |
CDK9-IN-15
|
852678-17-2
|
97.24%
|
|
|
CDK9-IN-15 is a potent small molecule CDK9 inhibitor, which can block the phosphorylation of positive transcription elongation factor b (P-TEFb) on the C-termina...
|
| T14916 |
CDK2-IN-4
|
2079895-42-2
|
97.24%
|
|
|
CDK2-IN-4 is a potent and selective inhibitor of CDK2 with an IC50 of 44 nM for CDK2/cyclin A. It shows 2,000-fold selectivity over CDK1/cyclin B with IC50 of 86...
|
| T2378 |
RGB-286638 free base
|
784210-88-4
|
97.29%
|
|
|
RGB-286638 free base is a novel CDK inhibitor with IC50s of 1 nM/2 nM/3 nM/4 nM/5 nM for cyclin T1-CDK9/cyclin B1-CDK1/cyclin E-CDK2/cyclin D1-CDK4/cyclin E-CDK3...
|
| T16750 |
Rigosertib
|
592542-59-1
|
97.33%
|
|
|
Rigosertib (ON-01910) is a selective and non-ATP-competitive inhibitor of PLK1 (IC50: 9 nM). Rigosertib is a multi-kinase inhibitor and a selective anti-cancer a...
|
| T60012 |
HS-243
|
848249-10-5
|
97.34%
|
|
|
HS-243 is an inhibitor of IRAK-4 and IRAK-1 with IC50s of 20 and 24 nM. HS-243 shows anti-inflammatory and anticancer activity.
|
| T60025 |
Eciruciclib
|
1868086-40-1
|
97.51%
|
|
|
Eciruciclib is an inhibitor of CDK with antitumor properties.
|
